Home › Categories › Science & Nature› Relatively Large RCT Studying Repurposed Drugs

Relatively Large RCT Studying Repurposed Drugs.pdf

GR-Slides-08-06-21.pdf

Preview of relatively large RCT studying repurposed drugs

🔗 Source: dcricollab.dcri.duke.edu

📊 Size: 4.4 MB

👤 Author: Cameron Chernecki

⬇️ Downloads: 296

Summary

The TOGETHER Adaptive Platform Trial is a clinical trial for early treatment of COVID-19 with repurposed therapies, led by Co-Principal Investigators Dr. Edward Mills and Dr. Gilmar Reis. The trial has several senior investigators, including Dr. Craig Rayner, Dr. Angela Reiersen, and Dr. Eric Lenze. Most COVID-19 clinical trials are small, with over half intending to recruit 100 patients or less, and a median sample size of 100. However, collectively, these trials represent a significant source of data, with over 74,054 participants. Useful trials, such as Remap-Cap, Solidarity, Recovery, Principle, and TOGETHER, are distinct from smaller, less meaningful trials.

Download File

Description

The TOGETHER Adaptive Platform Trial is a clinical trial for early treatment of COVID-19 with repurposed therapies, led by Co-Principal Investigators Dr.

Technical Information

File Format: PDF
File Size: 4.4 MB
Pages: 35
Language: EN
Author: Cameron Chernecki
Total Downloads: 296
Last Updated: 1 week ago

Document Overview

This PDF document about relatively large RCT studying repurposed drugs provides comprehensive information and guidance. Whether you're a beginner or advanced user, this resource offers valuable insights into relatively large RCT studying repurposed drugs.